Literature DB >> 28427503

Oesophageal cancer: Which treatment is the easiest to swallow? A review of combined modality treatments for resectable carcinomas.

Bianca So1, Loredana Marcu2, Ian Olver3, Raghu Gowda4, Eva Bezak5.   

Abstract

Oesophageal cancer is a relatively uncommon malignancy, but with poor prognosis. Despite several treatment options that are available, the 5-year survival rates rarely exceed 40%. This review discusses the main challenges of oesophageal cancer, the available treatment options, and the most effective treatment in terms of overall survival. The outcomes of clinical trials show that neo-adjuvant chemo-radiotherapy using cisplatin and 5-fluorouracil followed by oesophagectomy results in the greatest survival. However, the optimal chemotherapy and radiotherapy schedule remains unclear. There is no satisfactory treatment to date, particularly for patients with co-morbidities or advanced tumours.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Cisplatin; Clinical trials; Radiotherapy

Mesh:

Year:  2017        PMID: 28427503     DOI: 10.1016/j.critrevonc.2017.03.004

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  4 in total

1.  Thymoquinone Augments Cisplatin-Induced Apoptosis on Esophageal Carcinoma Through Mitigating the Activation of JAK2/STAT3 Pathway.

Authors:  Xue Hu; Jingjing Ma; Vikash Vikash; Jiao Li; Dandan Wu; Ya Liu; Jixiang Zhang; Weiguo Dong
Journal:  Dig Dis Sci       Date:  2017-12-02       Impact factor: 3.199

2.  Synergistic effects of low‑dose chemotherapy and T cells in renal cell carcinoma.

Authors:  Dan-Dan Xu; Men Ding; Pan Tong; Yan-Yun Chong; Wei-Yu Gu; Yang Li; Xin-Jiang Fang; Ning Li
Journal:  Oncol Rep       Date:  2020-07-07       Impact factor: 3.906

3.  Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy.

Authors:  Christopher Nevala-Plagemann; Samual Francis; Courtney Cavalieri; Randa Tao; Jonathan Whisenant; Robert Glasgow; Courtney Scaife; Shane Lloyd; Ignacio Garrido-Laguna
Journal:  ESMO Open       Date:  2018-07-25

4.  Functional disruption of the Golgi apparatus protein ARF1 sensitizes MDA-MB-231 breast cancer cells to the antitumor drugs Actinomycin D and Vinblastine through ERK and AKT signaling.

Authors:  Charlotte Luchsinger; Marcelo Aguilar; Patricia V Burgos; Pamela Ehrenfeld; Gonzalo A Mardones
Journal:  PLoS One       Date:  2018-04-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.